Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants may be without type 2 diabetes (T2D), or with T2D if their hemoglobin A1c (HbA1c) is 10% or lower
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:
* Coronary artery disease
* Cerebrovascular disease
* Peripheral arterial disease
* Chronic kidney disease defined as:
* eGFR \<45 millilitres/minute/1.73 meter squared (mL/min/1.73m\^2) and UACR \>30 milligram/gram (mg/g) (0.030 mg/mg)
* eGFR \<60 mL/min/1.73 m\^2 and UACR \>100 mg/g (0.100 mg/mg), or
* eGFR \<75 mL/min/1.73 m\^2 and UACR \>300 mg/g (0.300 mg/mg) (eGFR is calculated by central lab based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin c equation as determined by central lab)
A Body Mass Index of ≥27.0 kilograms per meter squared (kg/m\^2)
You may not be if
Diabetes related:
Participants have Type 1 Diabetes or any history of diabetic ketoacidosis
CV related:
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:
* Myocardial infarction
* Acute coronary syndrome
* Stroke, or
* Coronary, peripheral, or carotid artery arterial revascularization procedure.
Have acute decompensated heart failure requiring hospitalization.
Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
Kidney related:
Participants have an eGFR \<20 mL/min/1.73 m\^2 at screening
Have UACR \>5000 mg/g (5.000 mg/mg) at screening
Have received any form of dialysis ≤ 90 days from the date of randomization
Have either undergone a kidney transplant or have a transplant procedure scheduled
Other medical conditions:
Participants have had or plan to have a surgical treatment for obesity,
Have a history of chronic or acute pancreatitis
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2
Have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction
Clareo Health | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
